These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37918033)

  • 1. Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder.
    Carr MM; Wolkowicz NR; Cave S; Martino S; Masheb R; Midboe AM
    J Psychiatr Res; 2023 Dec; 168():204-212. PubMed ID: 37918033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
    Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
    Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
    Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
    Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in weight gain during medication-based treatment for opioid use disorder: A meta-analysis and retrospective analysis of clinical trial data.
    Manza P; Kroll D; McPherson KL; Johnson A; Dennis E; Hu L; Tai B; Volkow ND
    Drug Alcohol Depend; 2022 Sep; 238():109575. PubMed ID: 35868182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
    Finlay AK; Harris AH; Rosenthal J; Blue-Howells J; Clark S; McGuire J; Timko C; Frayne SM; Smelson D; Oliva E; Binswanger I
    Drug Alcohol Depend; 2016 Mar; 160():222-6. PubMed ID: 26832998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Quinones L; Rosenheck R
    Drug Alcohol Depend; 2016 Mar; 160():82-9. PubMed ID: 26804898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
    Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
    [No Abstract]   [Full Text] [Related]  

  • 12. Trends in Opioid Use Disorder Diagnoses and Medication Treatment Among Veterans With Posttraumatic Stress Disorder.
    Shiner B; Leonard Westgate C; Bernardy NC; Schnurr PP; Watts BV
    J Dual Diagn; 2017; 13(3):201-212. PubMed ID: 28481727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
    Manhapra A; Stefanovics E; Rosenheck R
    Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
    [No Abstract]   [Full Text] [Related]  

  • 15. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
    Kelly MM; Reilly E; Quiñones T; Desai N; Rosenheck R
    Drug Alcohol Depend; 2018 Feb; 183():111-117. PubMed ID: 29245103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
    Finlay AK; Wong JJ; Ellerbe LS; Rubinsky A; Gupta S; Bowe TR; Schmidt EM; Timko C; Burden JL; Harris AHS
    J Stud Alcohol Drugs; 2018 Nov; 79(6):909-917. PubMed ID: 30573022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
    Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
    J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.